Rumeysa Colak

Sancaktepe, Turkey

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Journal: BMC cancer
Published: June 04, 2026

Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey.

Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey.

Journal: OncoTargets and therapy
Published: May 12, 2026

Association Between ABO Blood Group and Survival in Early-Stage Colon Cancer: A Single-Center Retrospective Cohort Analysis.

Association Between ABO Blood Group and Survival in Early-Stage Colon Cancer: A Single-Center Retrospective Cohort Analysis.

Journal: Cancer management and research
Published: March 17, 2026

Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer.

Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer.

Journal: Medicina (Kaunas, Lithuania)
Published: March 02, 2026

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Journal: Journal of clinical medicine
Published: March 01, 2026

Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

Journal: Scientific reports
Published: February 17, 2026

Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study.

Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study.

Journal: Journal of neuro-oncology
Published: November 21, 2025

The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.

The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.

Journal: In vivo (Athens, Greece)
Published: July 25, 2025

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy.

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy.

Journal: Medicina (Kaunas, Lithuania)
Published: June 04, 2025

First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.

First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.

Journal: Journal of clinical medicine
Published: May 14, 2025

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Journal: Journal of clinical medicine
Published: May 11, 2025

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.

Journal: Anti-cancer drugs
Published: May 06, 2025
Showing 1-12 of 23

Last Updated: 09/26/2026